PACE-PRO: E-PROMs use with radical radiotherapy for prostate cancer

  • Research type

    Research Study

  • Full title

    The use of e-PROMs (electronic patient reported-outcome measures) for prostate cancer patients receiving radical radiotherapy.

  • IRAS ID

    337533

  • Contact name

    Sophy Shedwell

  • Contact email

    sophy.shedwell@qehkl.nhs.uk

  • Sponsor organisation

    The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 10 months, 30 days

  • Research summary

    PACE-PRO is a feasibility study to evaluate the use of e-PROMs (electronic patient-reported outcomes measures) to assess early side effects in prostate cancer patients receiving radical radiotherapy.

    Prostate cancer affects around 1 in 8 men in the UK. Radical radiotherapy is a safe, effective, and frequently used treatment for prostate cancer and uses higher doses of radiotherapy along with hormones.

    With advancing digital technology and NHS aims to provide and manage more community-based care, e-PROMs could be a useful tool to assess patient’s early side effects after radiotherapy. It could also promote patient involvement in their care and decision making as well as help the NHS use time and resources more efficiently and effectively.

    Paper versions of e-PROMs are regularly used as part of clinical trials for prostate cancer to assess side effects. This new idea hopes to assess side effects electronically as part of standard care using similar validated questions.

    The study aims to establish the acceptance and ease of use of the e-PROMs tool by study participants. To evaluate clinician’s feedback of e-PROMs, to assess its use in helping to inform patients clinical care and in making treatment decisions and to determine if e-PROMs can provide cost savings, by preventing the need for face-to-face clinic visits thus improving the service.

    The PACE-PRO study plans to recruit 20 men due to receive radical radiotherapy as part of their standard treatment for prostate cancer. The trial is planned to start September 2024 within the Macmillan Cancer Unit at King’s Lynn Hospital and will be completed and written up by July 2025. E-PROMs data will be completed by each participant via an e-PROMs tool before and after completion of radiotherapy treatment at 2 weeks, 4 weeks, 8 weeks and 12 weeks to help with the assessment of early side effects.

  • REC name

    London - Riverside Research Ethics Committee

  • REC reference

    24/PR/0919

  • Date of REC Opinion

    22 Aug 2024

  • REC opinion

    Further Information Favourable Opinion